ERYTECH Reports First Half 2017 Financial Results and Provides Business Update Post author:admERY Post published:September 11, 2017 Post category:Newsroom ERYTECH today provided a business update and reported its financial results for the six-month period ended June 30, 2017. You Might Also Like ERYTECH to report positive initial results on the use of GRASPA® in ALL patients allergic to E. Coli and Erwinia derived asparaginases at ASH November 7, 2014 ERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patients with Second-line Advanced Pancreatic Cancer October 25, 2021 ERYTECH Presents New Erymethionase Preclinical Findings at the 2019 AACR Annual Meeting April 1, 2019
ERYTECH to report positive initial results on the use of GRASPA® in ALL patients allergic to E. Coli and Erwinia derived asparaginases at ASH November 7, 2014
ERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patients with Second-line Advanced Pancreatic Cancer October 25, 2021
ERYTECH Presents New Erymethionase Preclinical Findings at the 2019 AACR Annual Meeting April 1, 2019
